To include your compound in the COVID-19 Resource Center, submit it here.

Allergan, generics contest sovereign immunity

Allergan plc (NYSE:AGN) and generic drug companies challenging patents covering dry-eye drug Restasis cyclosporine exchanged legal briefs about the pharma’s attempt to use tribal sovereign immunity to shield the patents from inter partes review.

The briefs were filed at the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB). They are not related to a recent decision by the

Read the full 606 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE